<DOC>
	<DOC>NCT02324985</DOC>
	<brief_summary>This study is designed to evaluate the analgesic safety and efficacy of study drug (AP0302) applied topically every 6 hours as compared to a vehicle, in subjects experiencing delayed onset muscle soreness.</brief_summary>
	<brief_title>Phase II Study of AP0302 5% Versus a Vehicle Comparator</brief_title>
	<detailed_description>The purpose of this study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in reducing pain/soreness associated with delayed onset muscle soreness (DOMS).</detailed_description>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>no clinically significant medical conditions BMI between 1830 negative drug, alcohol, pregnancy screens other protocoldefined inclusion criteria may apply no upper extremity workout in last 6 months no job requiring heavy lifting history of muscle disorders allergy or intolerance to study drug history of recent pain medication use other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>muscle soreness</keyword>
</DOC>